The stock is trending as investors react to Celularity’s sharper pivot toward longevity-focused cell therapy, a balance-sheet-improving asset sale, and a new commercial push tied to Florida’s regenerative medicine framework. For a low-priced biotech with listing and financing risks still in the background, that mix has created a high-volatility setup.
Meanwhile, CELU shares dropped 5.55% on Thursday, closing at $0.75.
Celularity Sharpens Its Longevity Pivot
The biggest catalyst is Celularity’s sale of its degenerative disease and biomaterials portfolio to NexGel Inc. (NXGL). The deal brought in $13.3 million in upfront consideration, including $8.3 million in cash and a $5.0 million convertible note. It also helped the company retire nearly $13 million of debt.
That does not solve Celularity’s financial challenges, but it gives the company more room to focus on its main strategy: placental-derived cell therapies for longevity, age-related diseases, and cellular medicine.
